2026-01-15 - Analysis Report
## Financial Report for Eli Lilly and Co (LLY)

### Company Overview
Eli Lilly and Co (LLY) is a multinational pharmaceutical corporation.

### Return Rate Analysis

- Cumulative return of review stock: **280.56%**
- Cumulative return of comparison stock (S&P 500, VOO): **93.94%**
- Divergence (max: 233.30, min: -31.10, current: 186.60, relative divergence: 82.30%)
- **The stock's return rate far exceeds the comparison stock's return rate, resulting in a significant divergence.**

### Alpha, Beta Analysis

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|--------|
| 2016-2018  | **37.0%** | **14.3%** | **33.0%** | **0.7** | **103.2B** |
| 2017-2019  | **36.0%** | **14.7%** | **19.0%** | **0.7** | **117.2B** |
| 2018-2020  | **30.0%** | **20.9%** | **10.0%** | **0.7** | **150.5B** |
| 2019-2021  | **49.0%** | **20.9%** | **5.0%** | **0.7** | **246.2B** |
| 2020-2022  | **59.0%** | **20.9%** | **60.0%** | **0.7** | **326.1B** |
| 2021-2023  | **116.0%** | **18.0%** | **115.0%** | **0.5** | **519.6B** |
| 2022-2024  | **123.0%** | **27.0%** | **104.0%** | **0.6** | **688.2B** |
| 2023-2025  | **183.0%** | **29.9%** | **121.0%** | **0.7** | **958.0B** |

### Stock Price Analysis

* Close: **$1,077.19**
* Last-market: $1070.47 (change: -0.62%)
* 5-day SMA: **$1,083.01**
* 20-day SMA: **$1,071.18**
* 60-day SMA: **$996.84**
* **The stock price fluctuates, indicated by the 5 and 20-day SMA values close to the current price.**

### Technical Analysis

* Market Risk Indicator (MRI): **0.70** (High Investment Recommended)
* RSI: **50.18**
* PPO: **-0.30**
* Hybrid Signal: Buy (Cash 0%)
Risk Level: Medium (MRI 0.70)
* Recent (20 days) relative divergence change: 1.50 (+)
* 7-day Rank change: -2 (-)
* 7-day Dynamic Expected Return change: 2.40 (+)
* Expected Return: **49.70%**
* **The stock's RSI and PPO values indicate neutral and bearish trends, respectively.**

### Recent News & Significant Events

* **[2026-01-11] This Healthcare Stock Could Be One of the Best Companies to Own in 2026 - The Motley Fool**
* **[2026-01-14] BMO Capital Markets Pounds the Table on Eli Lilly Stock (LLY) - TipRanks**
* **[2026-01-14] Eli Lilly and Company $LLY Stock Holdings Boosted by S Bank Fund Management Ltd - MarketBeat**
* **[2026-01-14] How Eli Lillyâ€™s US$1 Billion NVIDIA AI Lab Could Reshape Growth, Margins and Pipeline (LLY) - simplywall.st**
* **[2026-01-07] Eli Lilly (LLY) Stock Is Up, What You Need To Know - Yahoo Finance**
* **[2026-01-12] Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2026-2030 (Jan 2026) - 24/7 Wall St.**
* **[2026-01-14]  - Recent headlines suggest positive sentiment around the stock.**

### Analyst Opinions

* Analyst Consensus:
 - Key: Buy
 - Mean (1=StrongBuy~5=Sell): 1.70 (~Buy)
 - Opinions: 27
 - Target Price (avg/high/low): 1116.33 / 1500.00 / 770.00

### Recent Earnings Analysis

| Date | EPS | Revenue |
|-----|-----|---------|
| 2025-10-30 | 6.22 | 17.60 B$ |
| 2025-08-07 | 6.3 | 15.56 B$ |
| 2025-05-01 | 3.07 | 12.73 B$ |
| 2024-10-30 | 1.08 | 11.44 B$ |
| 2025-10-30 | 1.08 | 11.44 B$ |

* **Earnings per share (EPS) has seen a recent increase, while revenue seems stable.**

### Financial Information

### Revenue and Profitability

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $17.60B | 82.91% |
| 2025-06-30 | $15.56B | 84.27% |
| 2025-03-31 | $12.73B | 82.53% |
| 2024-12-31 | $13.53B | 82.24% |
| 2024-09-30 | $11.44B | 81.02% |

### Capital and Profitability

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $23.79B | 23.46% |
| 2025-06-30 | $18.27B | 30.98% |
| 2025-03-31 | $15.76B | 17.50% |
| 2024-12-31 | $14.19B | 31.07% |
| 2024-09-30 | $14.24B | 6.81% |

* **Profit margins have been consistently high, while return on equity (ROE) has seen some variation.**

### Comprehensive Analysis (Summary of previous items)

* The stock's return rate significantly exceeds the comparison stock's return rate.
* Technical analysis suggests a neutral and bearish trend.
* Recent earnings analysis indicates EPS growth but stable revenue.
* Analyst opinions suggest a strong buy rating.
* Financial information indicates high profit margins and varying ROE.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.